- In its sales forecast report Keytruda Of Roche, EvaluatePharma expects revenue of $4.06 billion by 2020. In September, pembrolizumab received accelerated approval from the FDA for the treatment of melanoma. Now the Company is working on a drug for non-small cell lung cancer (NSCLC), and other indications.
- Opdivo Of BMS extension it's the most valuable drug in development right now, says Lisa Urquhart, director of the editorial team at Evaluate, EP Vantage. “The data from the studies is showing some impressive progress in overall survival from the disease. “EvaluatePharma forecasts potential sales of Opdivo a 6 billion dollars by 2020.
- Genentech Of Roche, is still found in study trials for NSCLC, melanoma, RCC, and bladder cancer. The company received the breakthrough designation for this latest indication. EvaluatePharma puts revenue at $2.93 billioni by 2020.
- AstraZeneca is on the run with the drug MedImmune PD-L1 MEDI-4736, targeting NSCLC. A small study of 18 people showed a 28% response of MEDI-4736 in combination with CTLA-4tremelimumab antibodies. medi-4736 sell forecast close to $1.1 billion by 2019.
Read all about Pharmaceutical Executive November 2014
